GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) (GSK) closed at $50.33 on November 6, 2026, down 0.2% from the previous close, on volume of 2,910,923 shares (30-day average 5,284,576).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Calendar Call Spread | 20-Nov-26 : 19-Feb-27 45 C | 1,472 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Wisconsin reports measles-linked infant death as U.S. cases top 5,000
Seeking Alpha News (Fri, 6-Nov 12:18 PM ET)
Democratic lawmakers seen probing Trump drug pricing deals come January
Seeking Alpha News (Fri, 6-Nov 12:13 PM ET)
GSK Publishes Provisional 2027 Dividend Schedule
TipRanks (Fri, 6-Nov 10:27 AM ET)
Alector GAAP EPS of $1.11 beats by $1.10
Seeking Alpha News (Thu, 5-Nov 5:55 PM ET)
GSK Advances Early Ulcerative Colitis Study as Investors Watch Pipeline Potential
TipRanks (Thu, 5-Nov 11:34 AM ET)
GSK’s Nasal-Polyp Trial Advances, but Investors Await Data
TipRanks (Thu, 5-Nov 11:33 AM ET)
GSK Advances Phase 3 Asthma Trial, but Investors Await Results
TipRanks (Thu, 5-Nov 11:33 AM ET)
GSK Advances Liver Disease Drug Study as Investors Await Proof of Benefit
TipRanks (Thu, 5-Nov 11:33 AM ET)
GSK Tracks Long-Term Potential of Its Shigella Vaccine
TipRanks (Thu, 5-Nov 11:33 AM ET)
GSK Advances Inhaler Propellant Safety Study as Investors Await Results
TipRanks (Thu, 5-Nov 11:32 AM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of November 6, 2026, GSK stock price declined to $50.33 with 2,910,923 million shares trading.
GSK has a beta of 0.02, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.00 to the broad based SPY ETF.
GSK has a market cap of $100.88 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $12 billion in Revenue and $1.47 earnings per share. This beat revenue expectation by $148 million and exceeded earnings estimates by $.07.
In the last 3 years, GSK traded as high as $61.70 and as low as $31.72.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): AVDE, FENI, PPH, FVD, GMIE.
GSK has underperformed the market in the last year with a return of +10.7%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GSK shares. However, GSK has outperformed the market in the last 3 month and 2 week periods, returning -2.7% and -0.8%, while SPY returned -4.1% and -3.2%, respectively. This indicates GSK has been having a stronger performance recently.
GSK support price is $49.49 and resistance is $51.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK shares will trade within this expected range on the day.
